Short-course regimens for latent tuberculosis: what is ready for prime time?
Burman
William J
WJ
D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000502:physiology; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014376:Tuberculosis / Q000517:prevention & control*; D017735:Virus Latency
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; C018421:rifapentine